Astellas' investigational non-hormonal treatment demonstrates reduction in frequency and severity of moderate to severe vasomotor symptoms (VMS) associated with menopause TOKYO, Sept. 22, 2021 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback